Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 10/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | GLS2 | Q9UI32 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | MPEG1 | Q2M385 | 3/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29419667 | 0.86 | ACHE (0.47) | ACHEBACE1ALOX5PTGS2PTPN1 | |
| SCHEMBL11034240 | 0.74 | ALOX5 (0.40) | ACHEBACE1ALOX5PTGS2PTPN1 | |
| SCHEMBL28315488 | 0.74 | ACHE (0.39) | ACHEBACE1ALOX5PTGS2PTPN1 | |
| SCHEMBL5588331 | 0.72 | ACHE (0.42) | ACHEBACE1ALOX5PTGS2PTPN1 | |
| SCHEMBL27516481 | 0.72 | ACHE (0.42) | ACHEBACE1ALOX5PTGS2PTPN1 | |
| SCHEMBL11076693 | 0.68 | ACHE (0.53) | ACHEBACE1ALOX5PTGS2PTPN1 | |
| SCHEMBL13015757 | 0.68 | ACHE (0.53) | ACHEBACE1ALOX5PTGS2PTPN1 | |
| SCHEMBL19461836 | 0.68 | ACHE (0.53) | ACHEBACE1ALOX5PTGS2PTPN1 | |
| SCHEMBL17974000 | 0.67 | ALOX5 (0.55) | ACHEBACE1ALOX5PTGS2PTPN1 | |
| SCHEMBL26072897 | 0.67 | ALOX5 (0.70) | ACHEBACE1ALOX5PTGS2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2760834-B1 | PYRIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL MYERS SQUIBB CO (US) | 2016-11-16 | — | — | EP | disclosed |
| US-8933235-B2 | Pyridinedione carboxamide inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140235673-A1 | PYRIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY | 2014-08-21 | — | — | US | disclosed |
| EP-2760834-A1 | PYRIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | Bristol-Myers Squibb Company (US) | 2014-08-06 | — | — | EP | disclosed |
| WO-2013048930-A1 | PYRIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235673-A1 | PYRIDINEDIONE CARBOXAMIDE INHIBITORS OF ENDOTHELIAL LIPASE | LIPG, PNLIP, LPL | ACHE 356/4885BACE1 1626/4885ALOX5 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.